Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Genomics: Clinical Implementation » FDA Authorizes Adaptive Biotechnologies NGS Test for Minimal Residual Disease

FDA Authorizes Adaptive Biotechnologies NGS Test for Minimal Residual Disease

Oct 01, 2018
|
staff reporter

NEW YORK (GenomeWeb) — The US Food and Drug Administration on Friday granted de novo premarket authorization to Seattle-based Adaptive Biotechnologies' ClonoSeq, a next-generation sequencing test for measuring minimal residual disease (MRD) in acute lymphoblastic leukemia or multiple myeloma patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

To Keep Up

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

On the Rise in the City

The New York Times reports that a new viral variant of concern has been identified in New York City.

Nature Studies Present Single-Cell Map of Cell Cycle, Approach Identifies Cancer Treatment Resistance Pathways, More

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Issues New Guidance on SARS-CoV-2 Variants for Test Developers

  2. Novacyt Obtains CE Mark for Extraction-Free COVID-19 PCR Test

  3. Cue Health Nabs CE Mark for Molecular Point-of-Care COVID-19 Test

  4. Meridian Withdraws Emergency Use Authorization Application to FDA for Coronavirus MDx Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.